Q-omics provides the consensus-scored PODXL profile across patient tissues and cancer cell-line models. PODXL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PODXL is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, PODXL RNA expression shows 19,806 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where PODXL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PODXL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PODXL survival associations across molecular data types. PODXL RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PODXL RNA expression–survival associations across cancer types. High PODXL expression shows unfavorable associations in KIRP, MESO, UVM and LGG, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PODXL RNA expression.
This table summarizes PODXL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PODXL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PODXL shows lower tumor expression in KIRP, KICH, KIRC, LUAD and LUSC and higher tumor expression in LIHC. The KIRP box plot shows higher PODXL RNA expression in normal versus tumor tissue (log2 FC = −3.801, t-test p < 0.001).
This table shows molecular features associated with PODXL in patient tissues and cancer cell lines. In patient samples, PODXL shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PODXL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
